Features
Multi-agent clinical trial design
Protocol outline generation
Patient enrollment forecasting
Endpoint selection rationale
Regulatory compliance checklists (FDA, EMA, ICH)
Literature search and evidence synthesis
Feasibility assessment reports
Export to Word, PDF, and CDISC SDTM format
Adaptive trial design templates (Bayesian dose-finding)
Rare disease agent workflows with natural history comparisons
Custom agent building via no-code editor
API access for enterprise integrations (Professional plan)
Version control and audit trail
Real-time collaboration for design teams
Therapeutic area-specific templates (oncology, neurology, rare diseases)
Foundation model vBx-1.0 for precision neurology
Multimodal patient brain dataset: 12,000+ brains, 6,000 patients
Paired proteomic, genomic, and clinical data per patient
Physical inventory of 900+ frozen brain tissue samples
Virtual biopsy model predicts brain activity from blood draw
Target discovery from proprietary human data
Target characterization with 83% preclinical validation rate
Biomarker identification for clinical trials
Patient stratification for trial enrichment
Lifts responder fraction from 52% to 69% (vBx-1.0)
Reduces trial enrollment by 43% in Parkinson's (L-DOPA responders)
Platform for target discovery, characterization, biomarkers, and stratification
Supports Parkinson's, Alzheimer's, and other neurodegenerative diseases
Partnership model with top-20 pharma collaborations
